Search for: "Cephalon Inc."
Results 21 - 40
of 167
Sort by Relevance
|
Sort by Date
16 Jun 2015, 6:00 am
The Federal Trade Commission has reached a settlement resolving the antitrust suit charging Cephalon, Inc. with illegally blocking generic competition to its sleep disorder drug Provigil. [read post]
4 Jun 2015, 8:00 am
A federal judge in Pennsylvania has allowed the majority of a relator’s False Claims Act case against Cephalon Inc. to proceed, alleging a kickback scheme involving off-label drug marketing. [read post]
3 Jun 2015, 9:55 am
Cephalon, Inc., 36 F. [read post]
28 May 2015, 9:30 pm
Cephalon, Inc. settled with the Federal Trade Commission (FTC) for allegedly reducing competition by preventing the sale of generic versions of the sleep-disorder drug, Provigil. [read post]
1 Apr 2015, 11:51 am
On March 23, 2015, the United States District Court for the Eastern District of Pennsylvania denied certification of a nationwide class of third party payors (“TPPs”) asserting unjust enrichment claims against Cephalon, Inc. [read post]
12 Nov 2014, 10:15 am
Teva's subsidiary Celaphon had provided documents at the request of the city of Chicago on the basis that their trade secrets would be protected but that "since that time, in a series of written and verbal communications, the city took the position that it would disclose Cephalon's confidential documents to the press. [read post]
25 Jul 2014, 1:13 pm
Cephalon, Inc., is a third party payor case where plaintiffs – workers compensation insurers – claimed that they were injured by paying for prescriptions for defendant drug company’s pain medications which were written as a result of its alleged off-label marketing of the drug. [read post]
24 Jun 2014, 9:59 pm
Cephalon Inc. v. [read post]
9 Jun 2014, 11:25 am
Last month, as reported by the Los Angeles Times, the California counties of Orange and Santa Clara sued Actavis, Endo Health Solutions Inc., Johnson & Johnson's Janssen Pharmaceuticals, Purdue Pharma and Teva Pharmaceutical Industries' Cephalon Inc. for causing the national prescription drug epidemic. [read post]
2 Jun 2014, 4:43 am
Cephalon, Inc., No. 13-7167, 2014 U.S. [read post]
1 Jun 2014, 9:25 am
Cephalon Inc. v. [read post]
4 May 2014, 9:39 pm
Cephalon Inc. v. [read post]
23 Mar 2014, 8:49 pm
Cephalon Inc. v. [read post]
20 Mar 2014, 7:48 am
Cephalon, Inc. v. [read post]
13 Jan 2014, 4:02 am
Take for example, the pharmaceuticals case of Cephalon Inc v Orchid Europe Ltd [2010] EWHC 2945 (Pat) [briefly noted on PatLit here] in which Floyd J (as he was) treated the issue of who is likely to suffer the most irreparable harm as the key factor in the balance of convenience assessment itself: "Balance of convenienceThere is no dispute as to the approach which I should apply. [read post]
6 Jan 2014, 8:14 pm
Cephalon Inc. v. [read post]
3 Oct 2013, 7:07 am
Cephalon, Inc. et. al., 2-06-cv-02768 (PAED October 1, 2013, Order) (Goldberg, J.) [read post]
29 Jul 2013, 12:16 pm
Cephalon Inc. et al. v. [read post]
10 Jul 2013, 12:00 am
While synthesizing and screening compounds is considered routine experimentation, the Court noted in Cephalon, Inc. v. [read post]
1 Mar 2013, 2:30 pm
McNeil-PPC, Inc., 2009 WL 1178651, at *3-4 (Pa. [read post]
